Press release
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market on Track for Strong Growth, Estimated to Grow at 15.1% CAGR Through 2029
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market
What Is the Expected CAGR for the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Through 2025?
The market valuation for poly (adp-ribose) polymerase (parp) inhibitors has seen swift expansion presently, projected to escalate from $6.53 billion in 2024 to reach $7.49 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.8%. This upward trajectory throughout the past period is linked to several key factors, including the rising prevalence of cancer globally, greater adoption of genetic testing protocols, enhanced positive outcomes observed in ongoing clinical investigations, broader insurance accessibility, and a general increase in funding and progress within cancer research endeavors.
What's the Projected Size of the Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market by 2029?
Anticipation points toward a swift expansion in the poly (adp-ribose) polymerase (PARP) inhibitors market, which is projected to reach a valuation of $13.15 billion by the year 2029, exhibiting a compound annual growth rate (CAGR) of 15.1% throughout the forecast duration. This upswing is fueled by several key factors, including increased output and distribution of pharmaceutical agents, the escalating incidence of cancers associated with BRCA mutations, a higher occurrence rate of breast cancer globally, greater utilization of monoclonal antibodies in treatment protocols, and augmented spending within the healthcare sector. Over the upcoming years, significant developments set to influence the market involve progress in understanding biomarkers, the implementation of combination treatment regimens, the incorporation of artificial intelligence into the drug discovery pipeline, refinements in therapies guided by specific biomarkers, and the creation of novel, subsequent generations of PARP inhibitors.
View the full report here:
https://www.thebusinessresearchcompany.com/report/polyadp-ribose-polymerase-parp-inhibitors-global-market-report
Top Growth Drivers in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Industry: What's Accelerating the Market?
The increasing incidence of breast cancer is projected to fuel the expansion of the market for poly(ADP-ribose) polymerase (PARP) inhibitors in the coming period, as this condition involves the uncontrolled proliferation of breast cells resulting in a malignant tumor capable of metastasis; this surge in breast cancer cases is linked to various elements, including an aging global populace, shifts in lifestyle patterns, inherited genetic susceptibility, hormonal irregularities, higher body mass indexes, alcohol intake, and greater exposure to environmental hazards; PARP inhibitors function as a therapeutic aid for breast cancer sufferers by impeding the PARP enzyme's capacity to mend DNA lesions within malignant cells, thereby inducing cell mortality, especially in tumors carrying BRCA1 or BRCA2 mutations; to illustrate this impact, the National Breast Cancer Foundation indicated in January 2025 that an estimated one in eight females in the US will receive a breast cancer diagnosis within their lifespan, with data from 2024 showing 310,720 women and 2,800 men being diagnosed with invasive forms of the disease, consequently establishing the rising frequency of breast cancer as a principal catalyst for the PARP inhibitors market's advancement.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
What Trends Will Shape the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Through 2029 and Beyond?
Leading entities within the poly(ADP-ribose) polymerase (PARP) inhibitors field are concentrating efforts on pioneering sophisticated cancer therapeutics, specifically anticancer pharmaceuticals designed to address particular genetic alterations frequently observed in various malignancies. Anticancer agents function as treatments for cancer by inhibiting the proliferation of malignant cells, halting their dissemination, or inducing their demise. These pharmaceutical interventions operate via several pathways, which might involve disrupting cellular division cycles, obstructing vital proteins required for tumor expansion, or boosting the body's defense mechanisms against the illness. As an illustration, Zydus Lifesciences Limited, a pharmaceutical firm headquartered in India, introduced IBYRA in March 2024, representing a generic iteration of the PARP inhibitor olaparib within the Indian market, thereby offering patients suffering from HRD-positive and BRCA-positive cancers an economically viable and precise therapeutic alternative that substantially lowers the financial burden compared to the original patented medication.
What Are the Main Segments in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented -
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
Which Top Companies are Driving Growth in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
Major companies operating in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., Allarity Therapeutics Inc.
Which Regions Will Dominate the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Through 2029?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market on Track for Strong Growth, Estimated to Grow at 15.1% CAGR Through 2029 here
News-ID: 4281594 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for PARP
PARP Inhibitors Market Report- Expansive Coverage on the Profit Sources
The global PARP Inhibitors Market Size is valued at USD 3.8 Billion in 2024 and is predicted to reach USD 15.5 Billion by the year 2034 at a 15.2% CAGR during the forecast period for 2025-2034.
Request For Free Sample Pages :
https://www.insightaceanalytic.com/request-sample/1169
Poly (ADP-ribose) polymerase (PARP) inhibitors target a family of 17 enzymes responsible for catalyzing the formation of ADP-ribose chains (PAR chains) and transferring them to specific target proteins. These enzymes…
PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8…
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction
A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA.
Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html
Global PARP Inhibitors Market: Competition Landscape
Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is…
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These…
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report
The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.
The report analyses the global Lynparza market in detail along with the regional analysis as…
